The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Using frailty to determine CAR-T eligibility in patients with R/R multiple myeloma
Hamza Hashmi, MD, Medical University of South Carolina, Charleston, SC, discusses the impact of frailty on outcomes following CAR T-cell therapy for patients with relapsed/refractory (R/R) multiple myeloma (MM). Dr Hashmi suggests that frailty is a more accurate predictor of CAR-T efficacy than age, evidenced in real-world data that shows frail patients treated with idecabtagene vicleucel (ide-cel) or ciltacabtagene autoleucel (cilta-cel) have inferior outcomes compared to non-frail patients. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
